129 related articles for article (PubMed ID: 28062596)
1. Prediction of the Clinical SUV Ratio in Amyloid PET Imaging Using a Biomathematic Modeling Approach Toward the Efficient Development of a Radioligand.
Arakawa Y; Nai Y; Shidahara M; Furumoto S; Seki C; Okamura N; Tashiro M; Kudo Y; Yanai K; Gonda K; Watabe H
J Nucl Med; 2017 Aug; 58(8):1285-1292. PubMed ID: 28062596
[TBL] [Abstract][Full Text] [Related]
2. Parametric imaging and quantitative analysis of the PET amyloid ligand [(18)F]flutemetamol.
Heurling K; Buckley C; Van Laere K; Vandenberghe R; Lubberink M
Neuroimage; 2015 Nov; 121():184-92. PubMed ID: 26209803
[TBL] [Abstract][Full Text] [Related]
3. Validation of Noninvasive Tracer Kinetic Analysis of
Bullich S; Barthel H; Koglin N; Becker GA; De Santi S; Jovalekic A; Stephens AW; Sabri O
J Nucl Med; 2018 Jul; 59(7):1104-1110. PubMed ID: 29175981
[TBL] [Abstract][Full Text] [Related]
4. Kinetic Modeling of the Tau PET Tracer
Barret O; Alagille D; Sanabria S; Comley RA; Weimer RM; Borroni E; Mintun M; Seneca N; Papin C; Morley T; Marek K; Seibyl JP; Tamagnan GD; Jennings D
J Nucl Med; 2017 Jul; 58(7):1124-1131. PubMed ID: 27908967
[No Abstract] [Full Text] [Related]
5. PET quantification of 18F-florbetaben binding to β-amyloid deposits in human brains.
Becker GA; Ichise M; Barthel H; Luthardt J; Patt M; Seese A; Schultze-Mosgau M; Rohde B; Gertz HJ; Reininger C; Sabri O
J Nucl Med; 2013 May; 54(5):723-31. PubMed ID: 23471310
[TBL] [Abstract][Full Text] [Related]
6. Clinical validation of 18F-AZD4694, an amyloid-β-specific PET radioligand.
Cselényi Z; Jönhagen ME; Forsberg A; Halldin C; Julin P; Schou M; Johnström P; Varnäs K; Svensson S; Farde L
J Nucl Med; 2012 Mar; 53(3):415-24. PubMed ID: 22323782
[TBL] [Abstract][Full Text] [Related]
7. Quantitative Analysis of Amyloid Deposition in Alzheimer Disease Using PET and the Radiotracer ¹¹C-AZD2184.
Ito H; Shimada H; Shinotoh H; Takano H; Sasaki T; Nogami T; Suzuki M; Nagashima T; Takahata K; Seki C; Kodaka F; Eguchi Y; Fujiwara H; Kimura Y; Hirano S; Ikoma Y; Higuchi M; Kawamura K; Fukumura T; Böö ÉL; Farde L; Suhara T
J Nucl Med; 2014 Jun; 55(6):932-8. PubMed ID: 24732152
[TBL] [Abstract][Full Text] [Related]
8. Quantitative kinetic analysis of PET amyloid imaging agents [(11)C]BF227 and [(18)F]FACT in human brain.
Shidahara M; Watabe H; Tashiro M; Okamura N; Furumoto S; Watanuki S; Furukawa K; Arakawa Y; Funaki Y; Iwata R; Gonda K; Kudo Y; Arai H; Ishiwata K; Yanai K
Nucl Med Biol; 2015 Sep; 42(9):734-44. PubMed ID: 26093494
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the Feasibility of Screening Tau Radiotracers Using an Amyloid Biomathematical Screening Methodology.
Nai YH; Watabe H
Comput Math Methods Med; 2018; 2018():6287913. PubMed ID: 30662517
[TBL] [Abstract][Full Text] [Related]
10. Automated quantification of 18F-flutemetamol PET activity for categorizing scans as negative or positive for brain amyloid: concordance with visual image reads.
Thurfjell L; Lilja J; Lundqvist R; Buckley C; Smith A; Vandenberghe R; Sherwin P
J Nucl Med; 2014 Oct; 55(10):1623-8. PubMed ID: 25146124
[TBL] [Abstract][Full Text] [Related]
11. Reference Tissue-Based Kinetic Evaluation of 18F-AV-1451 for Tau Imaging.
Baker SL; Lockhart SN; Price JC; He M; Huesman RH; Schonhaut D; Faria J; Rabinovici G; Jagust WJ
J Nucl Med; 2017 Feb; 58(2):332-338. PubMed ID: 27587706
[TBL] [Abstract][Full Text] [Related]
12. Validation of the Semiquantitative Static SUVR Method for
Ottoy J; Verhaeghe J; Niemantsverdriet E; Wyffels L; Somers C; De Roeck E; Struyfs H; Soetewey F; Deleye S; Van den Bossche T; Van Mossevelde S; Ceyssens S; Versijpt J; Stroobants S; Engelborghs S; Staelens S
J Nucl Med; 2017 Sep; 58(9):1483-1489. PubMed ID: 28336779
[TBL] [Abstract][Full Text] [Related]
13. Determining Amyloid-β Positivity Using
Therriault J; Benedet AL; Pascoal TA; Savard M; Ashton NJ; Chamoun M; Tissot C; Lussier F; Kang MS; Bezgin G; Wang T; Fernandes-Arias J; Massarweh G; Vitali P; Zetterberg H; Blennow K; Saha-Chaudhuri P; Soucy JP; Gauthier S; Rosa-Neto P
J Nucl Med; 2021 Feb; 62(2):247-252. PubMed ID: 32737243
[TBL] [Abstract][Full Text] [Related]
14. Tracer Kinetic Analysis of (S)-¹⁸F-THK5117 as a PET Tracer for Assessing Tau Pathology.
Jonasson M; Wall A; Chiotis K; Saint-Aubert L; Wilking H; Sprycha M; Borg B; Thibblin A; Eriksson J; Sörensen J; Antoni G; Nordberg A; Lubberink M
J Nucl Med; 2016 Apr; 57(4):574-81. PubMed ID: 26795290
[TBL] [Abstract][Full Text] [Related]
15. Effect of Alzheimer Familial Chromosomal Mutations on the Amyloid Fibril Interaction with Different PET Tracers: Insight from Molecular Modeling Studies.
Balamurugan K; Murugan NA; Långström B; Nordberg A; Ågren H
ACS Chem Neurosci; 2017 Dec; 8(12):2655-2666. PubMed ID: 28898051
[TBL] [Abstract][Full Text] [Related]
16. 18F-florbetapir PET in patients with frontotemporal dementia and Alzheimer disease.
Kobylecki C; Langheinrich T; Hinz R; Vardy ER; Brown G; Martino ME; Haense C; Richardson AM; Gerhard A; Anton-Rodriguez JM; Snowden JS; Neary D; Pontecorvo MJ; Herholz K
J Nucl Med; 2015 Mar; 56(3):386-91. PubMed ID: 25655625
[TBL] [Abstract][Full Text] [Related]
17. Comparison of qualitative and quantitative imaging characteristics of [11C]PiB and [18F]flutemetamol in normal control and Alzheimer's subjects.
Mountz JM; Laymon CM; Cohen AD; Zhang Z; Price JC; Boudhar S; McDade E; Aizenstein HJ; Klunk WE; Mathis CA
Neuroimage Clin; 2015; 9():592-8. PubMed ID: 26640770
[TBL] [Abstract][Full Text] [Related]
18. [(18)F]Flutemetamol PET imaging and cortical biopsy histopathology for fibrillar amyloid β detection in living subjects with normal pressure hydrocephalus: pooled analysis of four studies.
Rinne JO; Wong DF; Wolk DA; Leinonen V; Arnold SE; Buckley C; Smith A; McLain R; Sherwin PF; Farrar G; Kailajärvi M; Grachev ID
Acta Neuropathol; 2012 Dec; 124(6):833-45. PubMed ID: 23053137
[TBL] [Abstract][Full Text] [Related]
19. A biomathematical modeling approach to central nervous system radioligand discovery and development.
Guo Q; Brady M; Gunn RN
J Nucl Med; 2009 Oct; 50(10):1715-23. PubMed ID: 19759115
[TBL] [Abstract][Full Text] [Related]
20. Performance characteristics of amyloid PET with florbetapir F 18 in patients with alzheimer's disease and cognitively normal subjects.
Joshi AD; Pontecorvo MJ; Clark CM; Carpenter AP; Jennings DL; Sadowsky CH; Adler LP; Kovnat KD; Seibyl JP; Arora A; Saha K; Burns JD; Lowrey MJ; Mintun MA; Skovronsky DM;
J Nucl Med; 2012 Mar; 53(3):378-84. PubMed ID: 22331215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
